Intracardiac Echocardiography Guided Watchman Device Implant

Sponsor
The Cleveland Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT06007872
Collaborator
(none)
100
1
1
49
2

Study Details

Study Description

Brief Summary

This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients. This study is aiming to show how the ICE is just as effective in placing the device correctly and effectively.

Condition or Disease Intervention/Treatment Phase
  • Device: Intracardiac Echocardiography (ICE)
N/A

Detailed Description

Left atrial appendage occlusion is approved as an indicated therapy for patients with non valvular atrial fibrillation, high risk of stroke and an appropriate rationale for avoidance of long term use of oral anticoagulants.

Concurrent procedural TEE is an integral part of the procedure. It is used to guide trans-septal puncture, device sizing and assessment of final adequacy of device implant.

TEE requires the participation and guidance of a cardiac imager and because the TEE probe is in place for a relatively long duration the procedure, the procedure is most commonly performed under general anesthesia. Furthermore TEE can be associated with risk of injury to the oropharynx and esophagus. Our ongoing clinical experience and known literature suggest that TEE may not be necessary for the overall success of the procedure. The objective of the study is to investigate a new work flow that may ultimately demonstrate that intra-procedural TEE may not be necessary, obviating the need for additional personnel, general anesthesia and decreasing overall risk. ICE has been widely used to aid trans-septal puncture and visualize left atrial anatomy. Smaller studies and case series have reported the use of ICE as an alternative to TEE in guiding Watchman device implant. This has not been compared systematically with TEE in a large patient sample.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Feasibility: Intracardiac Echocardiography Guided Watchman Device Implant
Actual Study Start Date :
Dec 2, 2022
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Intracardiac Echocardiography (ICE)

Device: Intracardiac Echocardiography (ICE)
ICE will be used to guide trans-septal puncture and to guide device implant.

Outcome Measures

Primary Outcome Measures

  1. Successful Watchman implantation using intracardiac echocardiography (ICE) guidance [During the procedure]

    Intracardiac echocardiography (ICE) guided Watchman placement confirmed by transesophageal echocardiography (TEE)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients who meet guideline established criteria for commercially available Watchman device implant and not enrolled in an active clinical trial
Exclusion Criteria:
  • Patients in whom a procedural TEE cannot be performed and an ICE only implant is needed.

  • Patients receiving a concomitant ablation procedure

  • Patients with prior incomplete surgical or percutaneous left atrial appendage ligation/exclusion procedures

  • Patients in whom the delivery of trans-septal equipment is anticipated to be difficult (e.g. patent foramen ovale (PFO) or atrial septal defect (ASD) closure devices in place).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Cleveland Ohio United States 44195

Sponsors and Collaborators

  • The Cleveland Clinic

Investigators

  • Principal Investigator: Shady Nakhla, MD, The Cleveland Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shady Nakhla, MD, Principal Investigator, The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT06007872
Other Study ID Numbers:
  • 22-1084
First Posted:
Aug 23, 2023
Last Update Posted:
Aug 31, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 31, 2023